Company intelligence / Profile preview

Alfact Innovation SAS

Paris, Ile-de-France, Franceorpha.net ↗

Ownership: Private
Development stage: Clinical

Overview

Alfact Innovation conducted clinical trials for ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute liver failure. In November 2013, they announced positive clinical trial results for the treatment of AIH- and HBV-related acute-on-chronic liver diseases.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Recombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Alfact Innovation SAS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfact Innovation SAS.

Explore the full profile